Otolith Labs develops a noninvasive wearable device utilizing patented Vestibular Resonance Therapy (nVRT) technology to treat chronic vertigo, affecting over 11 million Americans. The device requires no surgery or complex fittings, providing a safe and effective alternative to traditional treatments.
Funding
$34.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic vertigo affects millions, significantly impacting their quality of life. Traditional treatments often involve surgery or complex fittings, presenting challenges for many patients seeking relief.
Solution
Otolith Labs is developing a non-invasive wearable device that utilizes patented Vestibular Resonance Therapy (nVRT) to treat chronic vertigo. The headworn device is designed to be easy to use, requiring no surgery, advanced patient calibration, or complex fittings. Through clinical studies, the device has been tested on hundreds of subjects and is designed to be safe. The device aims to provide a safe and effective alternative for individuals seeking relief from chronic vertigo symptoms.
Target Audience
The primary target audience includes individuals suffering from chronic vertigo, as well as healthcare providers seeking non-invasive treatment options for their patients.
Features
- Non-invasive Vestibular Resonance Therapy (nVRT) technology
- Compact, headworn wearable design
- No surgery, advanced patient calibration, or complex fittings required
- Designed for safety, with testing on over 600 subjects
- Intended to manage the symptoms of vertigo